<DOC>
	<DOCNO>NCT02307058</DOCNO>
	<brief_summary>The BLaStM clinical trial extend Phase I LEAD trial compare LEAD upfront technique increase dose MP-MRI define GTVs HEIGHT method use moderate hypofractionated simultaneous integrate boost MP-MRI define GTVs course radiotherapy . The hypothesis alternate mechanism cell death , include bystander effect , put place dos 8 Gy per fraction use lattice effect local tumor eradication great use strategy .</brief_summary>
	<brief_title>MRI-Guided Prostate Boosts Via Initial Lattice Stereotactic vs Daily Moderately Hypofractionated Radiotherapy</brief_title>
	<detailed_description>Radiotherapy ( RT ) commonly apply primary ( initial definitive ) treatment alternative prostatectomy allow preservation anatomy potential improve functional outcome well tumor target normal tissue sparing . About 30-50 % men ultimately develop biochemical failure ( BF ) RT . Persistence disease dominant lesion indicate common mechanism responsible progression . Prostate cancer long natural history . BF typically precede clinical progression metastasis many year local persistence implicate . While survival 10 year high overall , quality life affect failure kind . Pathologic complete response ( PathCR ) standard ultrasound guide systematic prostate biopsy 2-3 year RT strong post-treatment ( post-Tx ) predictor patient outcome yet identify . Multiparametric-MRI ( MP-MRI ) parameter identify dominant tumor area prostate fairly high sensitivity specificity , MP-MRI direct biopsy , therefore , strengthen association prostate biopsy result patient outcome . The propose research compare two previously explore method ( LEAD HEIGHT ) escalate dose MP-MRI define prostate region directly address goal 1 ) improve local control via target radiotherapy ( RT ) dose escalation MP-MRI define high risk ( dominant ) tumor area use PathCR base MP-MRI-directed biopsy 2-2.5yr treatment primary endpoint ; 2 ) preserving quality life minimize dose nearby organ risk around prostate ; 3 ) establish relationship pre- serial post-Tx MP-MRI parameter PathCR .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Eligibility Criteria : A. Biopsy confirm adenocarcinoma ( include ductal ) prostate . B. T1T3 disease base digital rectal exam . C. No evidence metastasis clinical criterion available radiographic test ( N0M0 clinical imaging criterion ) . D. Gleason score 610 . E. Androgen deprivation therapy ( ADT ) discretion treat physician ; , must decide ( none , shortterm longterm count luteinizing hormonereleasing hormone ( LHRH ) agonist antagonist injection ) prior enrollment . An antiandrogen ( e.g. , bicalutamide 50 mg per day po ) recommend start prior LHRH agonist injection ( recommend LHRH antagonist injection ) recommend administered 4 month . However plan , follow restriction apply : . It may initiate 3 month prior sign consent ii . It must start prior start radiotherapy iii . The total length plan must ≤ 30 month F. Prostatespecific Antigen ( PSA ) ≤ 100 ng/mL within ( +/ ) 4 month sign consent . If PSA 100 drop &lt; 100 antibiotic , acceptable enrollment . G. Subjects T3 disease base digital rectal exam ( DRE ) , Gleason 810 PSA &gt; 15 ng/ml , bone scan within ( +/ ) 4 month sign consent without evidence metastasis . A questionable bone scan acceptable additional imaging study ( e.g. , plain xrays , CT , MRI ) confirm metastasis . H. Suspicious peripheral zone central gland lesion MPMRI . Peripheral zone : Distinct lesion dynamic contrastenhanced MRI ( DCEMRI ) early enhancement later washout ( Note : contrast required enrollment ) , and/or distinct lesion ADC map ( Value &lt; 1000 ) . ii . Central gland : A suspicious central gland lesion MPMRI must distinct lesion apparent diffusion coefficient ( ADC ) map ( Value &lt; 1000 ) I . No previous pelvic radiotherapy . J . No previous history radical/total prostatectomy ( suprapubic prostatectomy acceptable ) . K. No concurrent , active malignancy , nonmetastatic skin cancer early stage chronic lymphocytic leukemia ( welldifferentiated small cell lymphocytic lymphoma ) . If prior malignancy remission ≥ 5 year patient eligible . L. Ability understand willingness sign write informed consent document . M. Zubrod performance status ≤ 2 . ( Karnofsky Eastern Cooperative Oncology Group ( ECOG ) performance status may use estimate Zubrod ) . N. Willingness fill quality life/psychosocial form . O . Age ≥ 35 ≤ 85 year sign consent .</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
</DOC>